Tarah J. Ballinger, MD, discusses several trials in metastatic breast cancer (mBC) being presented at the upcoming 2022 American Society of Clinical Oncology Annual Meeting. The first study data that Dr Ballinger is excited to learn about are from DESTINY-Breast04, which evaluated patients with HER2-low tumor expression treated with trastuzumab deruxtecan, an antibody-drug conjugate (ADC) that has led to practice-changing results in patients with HER2-positive mBC. Next, Dr Ballinger looks forward to positive results from the TROPiCS-02 study on the efficacy of another ADC, sacituzumab govitecan, in patients with metastatic hormone-refractory breast cancer.
Dr Ballinger also awaits the results from the MAINTAIN trial which seeks to answer the question about whether to continue CDK4/6 inhibitors in patients with metastatic HR-positive breast cancer after progression of disease.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ASCO 2022: Advancing Therapies in Metastatic Breast Cancer - Medscape - May 26, 2022.